Cloning, purification and biochemical characterization of a thrombus-ditargeting thrombolytic agent, comprised of annexin B1, ScuPA-32K and fibrin-adherent peptide

Journal of Biotechnology

Volumn 126, Issue 3, 2006, Pages 394-405

  Ding, Fei Xiang ^a   Yan, Hong Li ^a   Lu, Yi Ming ^a   Xue, Geng ^a   Mei, Qian ^a   Huang, Jing Jing ^a   Zhao, Zhuan You ^b   Wang, Yu Zhao ^a   Sun, Shu Han ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Annexin B1; Biochemical characterization; Chimeric protein; Fibrin adherent peptide; ScuPA 32K; Thrombus ditargeting

Indexed keywords

ANNEXIN B1; BIOCHEMICAL CHARACTERIZATION; CHIMERIC PROTEINS; FIBRIN-ADHERENT PEPTIDE; SCUPA-32K; THROMBUS-DITARGETING;

BINDING ENERGY; BIOASSAY; BIOCHEMISTRY; BIOLOGICAL MEMBRANES; CLONING; PURIFICATION;

PROTEINS;

ANNEXIN B1; FIBRIN ADHERENT PEPTIDE; FIBRINOLYTIC AGENT; SINGLE CHAIN UROKINASE PLASMINOGEN ACTIVATOR 32K; UNCLASSIFIED DRUG; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BLOOD CLOT LYSIS; CHIMERA; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DRUG PURIFICATION; FIBRIN CLOT; FIBRINOLYSIS; IN VITRO STUDY; MALE; MEMBRANE BINDING; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE MEMBRANE;

ANIMALS; ANNEXINS; BLOOD COAGULATION; CLONING, MOLECULAR; CORONARY THROMBOSIS; DOGS; FIBRINOGEN; FIBRINOLYTIC AGENTS; HELMINTH PROTEINS; MALE; PEPTIDES; RECOMBINANT FUSION PROTEINS; URINARY PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

CANIS FAMILIARIS; THROMBUS;

EID: 33749524796     PISSN: 01681656     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2006.04.037     Document Type: Article

References (46)

1. Astrup T., and Mullertz S. The fibrin plate method for estimating fibrinolytic activity. Arch. Biochem. Biophys. 40 (1952) 346-351
2. Bailey K., Bettelheim F.R., Lorand L., and Middlebrook W.R. Action of thrombin in the clotting of fibrinogen. Nature 167 (1951) 233-234
3. Bell W.R. Present-day thrombolytic therapy: therapeutic agents-pharmacokinetics and pharmacodynamics. Rev. Cardiovasc. Med. 3 Suppl. 2 (2002) S34-S44
4. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
5. Cahill M.R., and Newland A.C. Platelet activation in coronary artery disease. Br. J. Biomed. Sci. 50 (1993) 221-234
6. Chang C.P., Zhao J., Wiedmer T., and Sims P.J. Contribution of platelet microparticle formation and granule secretion to the transmembrane migration of phosphatidylserine. J. Biol. Chem. 268 (1993) 7171-7178
7. Chen X.C., Hua Z.C., and Zhu D.X. Chemical conjugation of Gly-Pro-Arg-Pro. Tetrapeptide to low molecular weight urokinase. Biochem. Mol. Biol. Int. 39 (1996) 455-460
8. Collen D., Topol E.J., Tiefenbrunn A.J., Gold H.K., Weisfeldt M.L., Sobel B.E., Leinbach R.C., Brinker J.A., Yasuda T., Bulkley B.H., Robison A.K., Hutter Jr. A.M., Bell W.R., Spadaro Jr. J.J., Khaw B.A., and Grossbard E.B. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. Circulation 70 (1984) 1012-1017
9. Deckmyn H., Stanssens P., Hoet B., Declerck P.J., Lauwereys M., Gansemans Y., Tornai I., and Vermylen J. An echistatin-like Arg-Gly-Asp (RGD)-containing sequence in the heavy chain CDR3 of a murine monoclonal antibody that inhibits human platelet glycoprotein IIb/IIIa function. Br. J. Haematol. 87 (1994) 562-571
10. Deogny L., Weidenbach A., and Hampton J.W. Improved fibrin plate method for fibrinolytic activity measurements: use of bentonite precipitation and agar solidification. Clin. Chim. Acta 60 (1975) 85-89
11. Dewerchin M., and Collen D. Enhancement of the thrombolytic potency of plasminogen activators by conjugation with clot-specific monoclonal antibodies. Bioconjug. Chem. 2 (1991) 293-300
12. Edelberg J., and Pizzo S.V. Lipoprotein (a) regulates plasmin generation and inhibition. Chem. Phys. Lipids 67/68 (1994) 363-368
13. Freitag M., and Selker E.U. Expression and visualization of red fluorescent protein (RFP) in Neurospora crassa. Fungal Genet. Newslett. 52 (2005) 14-17
14. Gold H.K., Leinbach R.C., Garabedian H.D., Yasuda T., Johns J.A., Grossbard E.B., Palacios L., and Collen D. Acute coronary reocclusion after thrombolysis with recombinant human tissue type plasminogen activator: prevention by a maintenance infusion. Circulation 73 (1986) 347-352
15. Granger C.B., Califf R.M., and Topol E.J. Thrombolytic therapy for acute myocardial infarction. Drugs 44 (1992) 293-325
16. Hamelin J., Sarmientos P., Orsini G., and Galibert F. Implication of cysteine residues in the activity of single-chain urokinase-plasminogen activator. Biochem. Biophys. Res. Commun. 194 (1993) 978-985
17. Harrison D.G., Ferguson D.W., Collins S.M., Skorton D.J., Ericksen E.E., Kioschos J.M., Marcus M.L., and White C.W. Rethrombosis after reperfusion with streptokinase: importance of geometry of residual lesions. Circulation 69 (1984) 991-998
18. Ho S.N., Hunt H.D., Horton R.M., Pullen J.K., and Pease L.R. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77 (1989) 51-59
19. Holvoet P., Laroche Y., Lijnen H.R., Van Cauwenberge R., Demarsin E., Brouwers E., Matthyssens G., and Collen D. Characterization of a chimeric plasminogen activator consisting of a single-chain Fv fragment derived from a fibrin fragment D-dimer-specific antibody and a truncated single-chain urokinase. J. Biol. Chem. 266 (1991) 19717-19724
20. Hua Z.C., Chen X.C., Dong C., and Zhu D.X. Characterization of a recombinant chimeric plasminogen activator composed of Gly-Pro-Arg-Pro tetrapeptide and truncated urokinase-type plasminogen activator expressed in Escherichia coli. Biochem. Biophys. Res. Commun. 222 (1996) 576-583
21. Iwakura M., and Nakamura T. Effects of the length of a glycine linker connecting the N-and C-termini of a circularly permuted dihydrofolate reductase. Protein. Eng. 11 (1998) 707-713
22. Jiao J., Yu M., and Ru B. Characterization of a recombinant chimeric plasminogen activator with enhanced fibrin binding. Biochim. Biophys. Acta 1546 (2001) 399-405
23. Kalafatis M., Swords N.A., Rand M.D., and Mann K.G. Membrane-dependent reactions in blood coagulation: role of the vitamin K-dependent enzyme complexes. Biochim. Biophys. Acta 1227 (1994) 113-129
24. Laudano A.P., and Doolittle R.F. Synthetic peptide derivatives that bind to fibrinogen and prevent the polymerization of fibrin monomers. Proc. Natl. Acad. Sci. U.S.A. 75 (1978) 3085-3089
25. Laudano A.P., and Doolittle R.F. Studies on synthetic peptides that bind to fibrinogen and prevent fibrin polymerization. Structural requirements, number of binding sites, and species differences. Biochemistry 19 (1980) 1013-1019
26. Li X.Z., Zhang Y.S., Chen D.S., and Liu F.Y. Expression and characterization of a fusion protein consisting of ScuPA32k and fibrin-adherent peptide. Bull. Acad. Mil. Med. Sci. 21 (1997) 169-172
27. Lijnen H.R., Nelles L., Holmes W.E., and Collen D. Biochemical and thrombolytic properties of a low molecular weight form (comprising Leu144 through Leu411) of recombinant single-chain urokinase-type plasminogen activator. J. Biol. Chem. 263 (1988) 5594-5598
28. Marshak D.R., Kadonaga J.T., Burgess R.R., Knuth M.W., Brennan W.A., and Lin S.H. Strategies for Protein Purification and Characterization: A Laboratory Course Manual (1996), Cold Spring Harbor Laboratory Press, New York
29. Nishino N., Kakkar V.V., and Scully M.F. Influence of intrinsic and extrinsic plasminogen upon the lysis of thrombi in vitro. Thromb. Haemost. 66 (1991) 672-677
30. Neve R., Kissonerghis M., Clark J., Feldmann M., and Chernajovsky Y. Expression of an efficient small molecular weight tumour necrosis factor/lymphotoxin antagonist. Cytokine 8 (1996) 365-370
31. Rawles J. Guidelines for general practitioners administering thrombolytics. Drugs 50 (1995) 615-625
32. Robbie L.A., Booth N.A., Croll A.M., and Bennett B. The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis. Thromb. Haemost. 70 (1993) 301-306
33. Sabovic M., Lijnen H.R., Keber D., and Collen D. Correlation between progressive adsorption of plasminogen to blood clots and their sensitivity to lysis. Thromb. Haemost. 64 (1990) 450-454
34. Tait J.F., Engelhardt S., Smith C., and Fujikawa K. Prourokinase-annexin V chimeras. Construction, expression, and characterization of recombinant proteins. J. Biol. Chem. 270 (2001) 21594-21599
35. Tanaka K., Einaga K., Tsuchiyama H., Tait J.F., and Fujikawa K. Preparation and characterization of a disulfide-linked bioconjugate of annexin V with the B-chain of urokinase: an improved fibrinolytic agent targeted to phospholipid-containing thrombi. Biochemistry 35 (1996) 922-929
36. Thiagarajan P., and Benedict C.R. Inhibition of arterial thrombosis by recombinant annexin V in a rabbit carotid artery injury model. Circulation 96 (1997) 2339-2347
37. Towbin H., Staehelin T., and Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. U.S.A. 76 (1979) 4350-4354
38. Verstrete M. Third-generation thrombolytic drugs. Am. J. Med. 109 (2000) 52-58
39. Verstraete M., Lijnen H.R., and Collen D. Thrombolytic agents in development. Drugs 50 (1995) 29-42
40. Vrkljan M., Foster T.M., Powers M.E., Henkin J., Porter W.R., Staack H., Carpenter J.F., and Manning M.C. Thermal stability of low molecular weight urokinase during heat treatment. II. Effect of polymeric additives. Pharm. Res. 11 (1994) 1004-1008
41. Wun T.C., Schleuning W.D., and Reich E. Isolation and characterization of urokinase from human plasma. J. Biol. Chem. 257 (1982) 3276-3283
42. Yan H.L., Song Y.L., Liu F., He Y., and Sun S.H. Homology modeling three-dimensional structure of AnxB1 and reducing the immunogenicity by sequence deleted mutagenesis. Sci. Chin. C: Life. Sci. 25 (2004) 54-60
43. Yan H.L., Sun S.H., Chen R.W., and Guo Y.J. Cloning and functional identification of a novel annexin subfamily in Cysticercus cellulosae. Mol. Biochem. Parasitol. 119 (2002) 1-5
44. Yan H.L., Wang W.T., He Y., Zhao Z.Y., Gao Y.J., Zhang Y., and Sun S.H. Construction, expression, and characterization of a recombinant annexin B1-low molecular weight urokinase chimera in Escherichia coli. Acta Biochim. Biophys. Sin. 36 (2004) 184-190
45. 2+-dependent phospholipid-binding protein, on coagulation time and thrombosis. Sci. Chin. C: Life. Sci. 23 (2002) 378-380
46. Zhao Z.Y., Liu B.F., Liu H.X., Sun Z.Y., Zhang J., and Liu J.N. Pharmalogical effects of recombinant human prourokinase. J. Nanjing Univ. (Natural Sciences) 37 (2001) 420-433